Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Altamira Therapeutics Ltd. (CYTOF)
:CYTOF
Holding CYTOF?
Track your performance easily
CYTOF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.07 - $3.49
Previous CloseN/A
Volume627.00
Average Volume (3M)57.42K
Market Cap
$498.76K
Enterprise Value$2.65M
Total Cash (Recent Filing)$32.44M
Total Debt (Recent Filing)$10.15M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Apr 09, 2025EPS Estimate
-0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding3,778,524
10 Day Avg. Volume18,390
30 Day Avg. Volume57,423
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)100.49
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-2.40
Enterprise Value/Market Cap5.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit97.09
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Ownership Overview
―
Insiders
0.06% Mutual Funds
2.68% Other Institutional Investors
97.26% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CYTOF FAQ
What was Altamira Therapeutics Ltd.’s price range in the past 12 months?
Altamira Therapeutics Ltd. lowest stock price was $0.07 and its highest was $3.49 in the past 12 months.
What is Altamira Therapeutics Ltd.’s market cap?
Altamira Therapeutics Ltd.’s market cap is $498.76K.
When is Altamira Therapeutics Ltd.’s upcoming earnings report date?
Altamira Therapeutics Ltd.’s upcoming earnings report date is Apr 09, 2025 which is in 76 days.
How were Altamira Therapeutics Ltd.’s earnings last quarter?
Altamira Therapeutics Ltd. released its earnings results on Sep 24, 2024. The company reported -$1.95 earnings per share for the quarter, beating the consensus estimate of -$2.338 by $0.388.
Is Altamira Therapeutics Ltd. overvalued?
According to Wall Street analysts Altamira Therapeutics Ltd.’s price is currently Overvalued.
Does Altamira Therapeutics Ltd. pay dividends?
Altamira Therapeutics Ltd. does not currently pay dividends.
What is Altamira Therapeutics Ltd.’s EPS estimate?
Altamira Therapeutics Ltd.’s EPS estimate is -0.54.
How many shares outstanding does Altamira Therapeutics Ltd. have?
Altamira Therapeutics Ltd. has 3,778,524 shares outstanding.
What happened to Altamira Therapeutics Ltd.’s price movement after its last earnings report?
Altamira Therapeutics Ltd. reported an EPS of -$1.95 in its last earnings report, beating expectations of -$2.338. Following the earnings report the stock price went up 4.478%.
Which hedge fund is a major shareholder of Altamira Therapeutics Ltd.?
Currently, no hedge funds are holding shares in CYTOF
---
Company Description
Altamira Therapeutics Ltd.
Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The firm focuses on the development of intranasal betahistine for the treatment of vertigo and for the prevention of antipsychotic-induced weight gain and somnolence. It also includes other programs under development such as Keyzilen, for the treatment of acute inner ear tinnitus; and Sonsuvi, for the treatment of acute inner ear hearing loss. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.
---
CYTOF Earnings Call
Q2 2024
0:00 / 0:00
---
Technical Analysis
---